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Abstract
Background: The roles of carcinoembryonic antigen (CEA), cytokeratin 19 fragments (CYFRA21-1) and neuron-specific
enolase (NSE) in metastases occurrence and poor diagnosis in specific histological classifications of lung cancer need
further exploring. In this study, we investigated relationship between elevated levels of three biomarkers of CEA, CYFRA21-1
and NSE (individually and in combination) and metastasis, survival status and prognosis in lung cancer patients.
Methods: Eight hundred and sixty eight lung cancer patients including adenocarcinoma (ADC, N = 445), squamous cell
carcinoma (SCC, N= 215), small cell lung cancer (SCLC, N= 159) and other types (N= 49) were categorized into negative,
moderate and high groups according to serum levels of biomarkers, and were then categorized into negative, single,
double and triple groups according to any positive combination of three biomarkers. The cutoff values of three biomarkers
for groupings were developed on the training group (N = 432) and verified in a validation group (N= 436). Clinical and
laboratory characteristics were then assessed for correlation with occurrence of metastasis, survival status and prognosis
between the two groups. Further correlation analyses were also conducted by different subtypes (ADC, SCC and SCLC)
and tumor stages (I + II, III and IV) of lung cancers.
Results: The consistent results between training and validation group confirmed the rationality of grouping methods.
CYFRA21-1 levels had stronger association with metastases and survival status than CEA and NSE in all lung cancer
patients. When stratified by subtypes, these significances only existed in ADC patients for CYFRA21-1. Cox regression
analyses showed that CYFRA21-1 and NSE were independent prognostic factors for lung cancer patients. However,
only CYFRA21-1 was an independent prognostic factor in ADC and SCLC patients subtypes. Cox-regression results also
indicated that CYFRA21-1 could act as independent prognostic factor in different stages (I + II, III and IV) of lung cancer.
Conclusion: CYFRA21-1 was more important in metastasis occurrence and in predicting poor prognosis in lung cancer
patients than CEA, NSE and positive numbers of biomarkers.
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Background
Globally, lung cancer has the highest associated mortality
among all malignant cancers [1]. The 5-year survival rate in
advanced stage cancers is 15%, as compared to 80% in early
stage lung cancers [2]. One of the reasons is that most
patients are diagnosed at advanced stages due to lack of
sensitive and specific early diagnostic biomarkers [3]. Non-
small-cell lung cancer (NSCLC) accounts for approximately
85% of all lung cancers; the remaining 15% cases are
classified as small cell lung cancer (SCLC) [4]. Although
chemotherapy and targeted therapy are the main clinical
treatment especially of stage IV patients, yet there is only
4–5% improvement in 5-year survival rates for stage I-III
patients, and no significant improvement for stage IV
patients [5]. The diagnostic methods include chest x-ray,
computed tomography (CT) and needle biopsy of lung
[6, 7]. However, the high cost and/or invasive nature of
these investigations limit the widely use in clinical diagnosis.
During past decades, many advances have been made in
the identification of tumor-associated markers in body fluids
such as plasma, serum or bio-aerosols such as exhaled
breath condensate (EBC) [8, 9]which could facilitate early
detection and help for treatment monitoring [10]. For lung
cancer diagnosis, the leading markers used are carcinoem-
bryonic antigen (CEA), cytokeratin 19 fragments (CYFRA
21–1) and neuron-specific enolase (NSE). CEA, which is
closely related to histological classification, is considered
valuable for diagnosis of ADC [11]. CYFRA 21–1 and NSE
are used for the diagnosis of SCLC [12, 13]. Increasing trend
in levels of CEA, CYFRA21-1 and NSE have been associated
with metastasis and poor prognosis [14–16]. However, limi-
tations of previous studies are either in small sample sizes
(N= 200-300) or not analyzed in combinations.
In this retrospective study we evaluated the predictive
values of serum levels of CEA, CYFRA21-1 and NSE for
prognosis and occurrence of metastasis, and the association
of these biomarkers with clinical characteristics.
Methods
Patients
This study recruited 868 lung cancer patients who were ad-
mitted to West China Hospital between 2008 through 2012.
All data were obtained from medical records within 2 weeks
of diagnosis, and information regarding metastasis was ob-
tained through reports of whole-body CT scan, bone scan,
lymph node and fiber optic bronchoscopy biopsy. Survival
time was obtained during subsequent follow-up visit or tele-
phonic inquiry. Those patients who did not receive CEA,
CYFRA21-1 and NSE determinations and lack of follow-up
data were excluded. Data on stage were according to the
TNM Classification of Malignant Tumors, 7th Edition [17].
The overall survival time was calculated as time from the
date of diagnosis through the date of death or last follow
up visit (if the exact date of death was unavailable). Prior to
surgery or any other treatments, serum concentrations of
CEA, CYFRA21-1 and NSE were measured by immunoas-
says. Based on the reported literatures, the threshold values
for CEA, CYFRA21-1 and NSE levels were 3.4 ng/mL,
3.0 ng/mL and 15.0 ng/mL, respectively [17].
Study design
Depending on the levels of CEA, CYFRA21-1 and NSE, the
study subjects were divided into three groups (negative,
moderate and high). For CEA analysis, moderate and high
groups were defined as 1–10 folds and >10 folds cutoff
value, respectively. For CYFRA21-1 analysis 1–3 folds and
>3 folds, respectively. For NSE analysis, 1–2 folds and >2
folds, respectively. This analysis was performed in a ran-
domly selected training group (N = 432), reserving the left
436 cases for validation. The cutoff values of three bio-
markers for groupings were developed on the training
group and tested in a validation group.
Next, we determined the correlations of biomarker
levels with three main histological subtypes, ADC, SCC
and SCLC. The association analyses of other tumor types
(N = 49) such as large cell lung cancers and adenosqua-
mous carcinoma were also performed which showed no
positive prognostic value (Data not shown).
Finally, the diagnosis, metastasis and prognostic values of
combination patterns of three biomarkers were also evalu-
ated. In brief, patients were grouped as negative, single,
double and triple positive of biomarkers. Negative indicated
that serum levels of all three biomarkers were below cutoff
levels. Single, double, triple positive meant that concentra-
tions of any one, two or all three biomarkers exceeded
cutoff values.
Statistical methods
SPSS 19.0 for Windows (SPSS Inc, Chicago, USA) was used
for data analyses. Chi-square test was performed to evaluate
the inter-group differences. Kaplan-Meier test was used to
calculate the survival status of different groups, and Log-
rank test was used to compare the survival among three
groups. Multivariate Cox regression analysis was used to
determine the clinical characteristics, metastasis and
survival status in order to estimate the hazards ratio for
different serum levels of CEA, CYFRA21-1 and NSE and
identify independent predictors of poor prognosis.
Results
Increased levels of CYFRA21-1 significantly correlated
with metastatic disease
Total 868 lung cancer patients were randomly divided into
training group (TA, 432 cases) and validation (VA, 436
cases) group to confirm the rationality of grouping
methods. Among them, 320 patients tested negative (TA:
164, VA: 156) (<3.4 ng/mL) while 365 (TA: 179, VA: 186)
and 210 (TA: 89, VA: 94) had moderate and high levels of
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Table 1 The analysis of CYFRA21-1 in all lung cancer patients
No. (%)
Neg Moderate High Total P Value
1–3 fold >3 fold
(n = 115) (n = 190) (n = 127) (n = 432)
Basic Characteristics
Age
< 45 5 (4.3) 16 (8.4) 7 (5.5) 28 0.101
45–60 58 (50.4) 72 (37.9) 46 (36.2) 176
> 60 52 (45.3) 102 (53.7) 74 (58.3) 228
Sex
Male 79 (68.7) 134 (70.5) 83 (65.4) 296 0.623
Female 36 (31.3) 56 (29.5) 44 (34.6) 136
Histological classification
SCC 21 (18.3) 42 (22.1) 56 (44.1) 119
ADC 64 (55.7) 103 (54.2) 58 (45.7) 225 <0.001**
SCLC 22 (19.1) 34 (17.9) 7 (5.5) 63
Others 8 (6.9) 11 (5.8) 6 (4.7) 25
Stages
I 12 (10.4) 6 (3.2) 0 (0.0) 18 <0.001**
II 7 (6.1) 8 (4.2) 2 (1.6) 17
III 40 (34.8) 50 (26.3) 38 (29.9) 128
IV 49 (42.6) 115 (60.5) 79 (62.2) 243
#Un. 7 (6.1) 11 (5.8) 8 (6.3) 26
Smoke status
No 55 (47.8) 80 (42.1) 56 (44.1) 191 0.621
Yes 60 (52.2) 110 (57.9) 71 (55.9) 241
Metastasis
Brain
No 104 (90.4) 162 (85.3) 105 (82.7) 371 0.212
Yes 11 (9.6) 28 (14.7) 22 (17.3) 61
Bone
No 101 (90.4) 142 (74.7) 92 (72.4) 335 <0.01**
Yes 14 (9.6) 48 (25.3) 35 (27.6) 97
Liver
No 113 (98.3) 170 (89.5) 108 (85.0) 391 <0.01**
Yes 2 (1.7) 20 (10.5) 19 (15.0) 41
Adrenal gland
No 113 (98.3) 173 (91.1) 119 (93.7) 405 <0.05*
Yes 2 (1.7) 17 (8.9) 8 (6.3) 27
Lymph node
No 66 (57.4) 68 (35.8) 37 (29.1) 171 <0.001***
Yes 49 (42.6) 122 (64.2) 90 (70.9) 261
Intrapulmonary
No 105 (91.3) 163 (85.8) 111 (87.4) 379 0.360
Table 1 The analysis of CYFRA21-1 in all lung cancer patients
(Continued)
Yes 21 (9.1) 58 (14.9) 35 (14.2) 53
Pleural
No 100 (87.0) 170 (89.5) 98 (77.2) 368 <0.01**
Yes 15 (13.0) 20 (10.5) 29 (22.8) 64
Mediastinal
No 113 (98.3) 185 (97.4) 120 (94.5) 418 0.208
Yes 2 (1.7) 5 (2.6) 7 (5.5) 14
Peritoneum
No 115 (100) 178 (93.7) 116 (91.3) 409 <0.01**
Yes 0 (0.0) 12 (6.3) 11 (8.7) 23
Validation group
No. (%)
Neg Moderate High Total P Value
1–3 fold >3 fold
(n = 116) (n = 200) (n = 120) (n = 436)
Basic Characteristics
Age
8 (6.9) 13 (6.5) 10 (8.3) 31 0.073
52 (44.8) 61 (30.5) 36 (30.0) 149
56 (48.3) 126 (63.0) 74 (61.7) 256
Sex
74 (63.8) 139 (69.5) 94 (78.3) 307 <0.05*
42 (36.2) 61 (30.5) 26 (21.7) 129
Histological classification
15 (12.9) 43 (21.5) 38 (31.7) 96 <0.001**
56 (48.3) 98 (49.0) 66 (55.0) 220
40 (34.5) 47 (23.5) 9 (7.5) 96
5 (4.3) 12 (6.0) 7 (5.8) 24
Stages
9 (7.8) 9 (4.5) 4 (3.3) 22 <0.05*
15 (12.9) 20 (10.0) 3 (2.5) 38
23 (19.8) 43 (21.5) 23 (19.2) 89
61 (52.6) 115 (57.5) 86 (71.7) 262
8 (6.9) 13 (6.5) 4 (3.3) 25
Smoke status
63 (54.3) 86 (43.0) 42 (35.0) 191 <0.05*
53 (45.7) 114 (57.0) 78 (65.0) 245
Metastasis
Brain
102 (87.9) 183 (91.5) 93 (77.5) 378 <0.01**
14 (12.1) 17 (8.5) 27 (22.5) 58
Bone
101 (87.1) 160 (80.0) 79 (65.8) 340 <0.001***
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CEA, respectively. For CYFRA21-1, 231 patients tested
negative (TA: 115, VA: 116) while 390 (TA: 190, VA: 200)
and 247 (TA: 127, VA: 120) had moderate and high levels,
respectively. For NSE, 412 patients (TA: 206, VA: 206)
tested negative while 256 (TA: 128, VA 128) and 200 (TA:
98, VA: 102) had moderate and high levels.
The results indicated strong correlations of increased
levels of CEA, CYFRA21-1 and NSE with histological clas-
sifications in both TA and VA groups (All P < 0.001). CEA
and CYFRA21-1 were also related closely to TNM stages in
TA and VA groups (P < 0.05, P < 0.01 and P < 0.001), while
NSE had dramatic correlation with smoke status (TA: P <
0.01, VA: P < 0.05). CEA correlated closely to bone metasta-
sis (TA: P < 0.05, VA: P < 0.01) and NSE had significant
correlation with metastasis of bone (TA: P < 0.001, VA: P <
0.01), liver (TA: P < 0.001, VA: P < 0.01), lymph node (TA:
P < 0.01, VA: P < 0.01) and mediastinum (TA: P < 0.01, VA:
P < 0.05) (Table 1, Additional file 1: Table S1A and B).
Among all three biomarkers, levels of CYFRA21-
1significantly correlated with occurrence of organ metas-
tasis. Besides metastasis to bone (TA: negative9.6%, mod-
erate 25.3%, high 27.6%, P < 0.01; VA: negative 12.9%,
moderate 20.0%, high 34.2%; P < 0.001) and liver (TA:
negative 1.7%, moderate10.5%, high 15.6%, P < 0.01; VA:
Table 1 The analysis of CYFRA21-1 in all lung cancer patients
(Continued)
15 (12.9) 40 (20.0) 41 (34.2) 96
Liver
110 (94.8) 177 (88.5) 96 (80.0) 383 <0.01**
6 (5.2) 23 (11.5) 24 (20.0) 53
Adrenal gland
107 (92.2) 192 (96.0) 110 (91.7) 409 0.213
9 (7.8) 8 (4.0) 10 (8.3) 27
Lymph node
58 (50.0) 68 (34.0) 41 (34.2) 167 <0.01**
58 (50.0) 132 (66.0) 79 (65.8) 269
Intrapulmonary
105 (90.5) 169 (84.5) 101 (84.2) 375 0.262
11 (9.5) 31 (15.5) 19 (15.8) 61
Pleural
107 (92.2) 168 (81.5) 95 (79.2) 365 <0.05*
9 (7.8) 37 (18.5) 25 (20.8) 71
Mediastinal
114 (98.3) 192 (96.0) 112 (93.3) 418 0.161
2 (1.7) 8 (4.0) 8 (6.7) 18
Peritoneum
111 (95.7) 189 (94.5) 99 (82.5) 399 <0.01**
5 (4.3) 11 (5.5) 21 (17.5) 37
*p < 0.05, **p < 0.001, #Un., unknown
Table 2 The association analysis between CYFRA21-1 and ADC
No. (%)
Neg Moderate High Total P Value
(1–3 fold) >3 fold
(n = 120) (n = 201) (n = 124) (n = 445)
Basic Characteristics
Age
< 45 years 5 (4.2) 22 (11.0) 14 (11.3) 41 <0.05*
45–60 years 57 (47.5) 66 (32.8) 38 (30.6) 161
> 60 years 58 (48.3) 113 (56.2) 72 (58.1) 243
Sex
Male 65 (54.2) 112 (55.7) 71 (57.3) 248 0.889
Female 55 (45.8) 89 (44.3) 53 (42.7) 197
Stages
I + II 24 (20.0) 14 (7.0) 5 (4.0) 43 <0.001**
III + IV 91 (75.8) 181 (90.0) 116 (93.6) 388
Unknown 4 (4.2) 6 (3.0) 3 (2.4) 14
Smoke status
No 79 (65.9) 119 (59.2) 68 (54.8) 266 0.208
Yes 41 (34.1) 82 (40.8) 56 (45.2) 179
Metastasis
Brain
No 107 (89.2) 164 (81.6) 95 (76.6) 366 <0.05*
Yes 13 (10.8) 37 (18.4) 29 (23.4) 79
Bone
No 102 (85.0) 141 (70.1) 75 (60.5) 318 <0.001**
Yes 18 (15.0) 60 (29.9) 49 (39.5) 127
Liver
No 116 (96.7) 181 (90.1) 102 (82.3) 399 <0.05*
Yes 4 (3.3) 20 (9.9) 22 (17.7) 46
Adrenal gland
No 115 (95.8) 191 (95.0) 116 (93.5) 422 0.713
Yes 5 (4.2) 10 (5.0) 8 (6.5) 23
Lymph node
No 69 (57.5) 69 (34.3) 45 (36.3) 183 <0.001**
Yes 51 (42.5) 132 (65.7) 79 (63.7) 262
Intrapulmonary
No 111 (92.5) 165 (82.1) 105 (84.7) 381 <0.05*
Yes 9 (7.5) 36 (17.9) 19 (15.3) 64
Pleural
No 103 (85.8) 161 (80.1) 88 (71.0) 352 <0.05*
Yes 17 (14.2) 40 (19.9) 36 (29.0) 93
Mediastinal
No 119 (99.2) 195 (97.0) 118 (95.2) 432 0.178
Yes 1 (0.8) 6 (3.0) 6 (4.8) 13
Peritoneum
No 119 (99.2) 186 (92.5) 107 (86.3) 412 <0.05*
Yes 1 (0.8) 15 (7.5) 17 (13.7) 33
*p<0.05, **p<0.001
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negative 5.2%, moderate11.5%, high 20.0%; P < 0.001),
CYFRAY21-1 levels were also associated with metastases
to lymph nodes (TA: negative 42.6%, moderate 64.2%,
high 70.9%, P < 0.001; VA: negative 50%, moderate 66%,
high 65.8%; P < 0.01), pleura (TA: P < 0.01, VA: P < 0.05)
and peritoneum (TA: P < 0.01, VA: P < 0.01) (Table 1).
However, CEA and NSE levels showed relative poor correl-
ation with metastases (Additional file 1: Table S1A and B),
which confirmed the importance of CYFRA21-1 in metas-
tasis. Consistent results between training and validation
groups also indicated the grouping rationality although
several deviations such as sex, brain metastasis and adrenal
gland metastasis in CYFRA21-1 and NSE, while brain and
liver metastasis in CEA (Table 1, Additional file 1: Table
S1A and B).
Correlation of CYFRA21-1 and NSE with metastases in
ADC and SCC, respectively
In this study, the CYFRA21-1 levels showed a stronger
correlation with occurrence of metastasis in ADC patients
when compared with that of CEA and NSE. It also showed
a significant correlation with presence of metastatic
lesions in brain (P < 0.05), bone (P < 0.001), liver (P < 0.05),
lymph node (P < 0.001), intrapulmonary (P < 0.05), pleural
(P < 0.05) and peritoneum (P < 0.05) (Table 2). However,
CEA positive levels correlated only with bone (P < 0.05)
and liver metastasis (P < 0.05) (Additional file 2: Table S2A),
while NSE levels correlated only with metastatic lesions in
brain (P < 0.001) and bone (P < 0.001) (Additional file 2:
Table S2B).
An interesting finding which differs from those reported
earlier is the significant correlation of NSE levels with oc-
currence of metastasis in SCC patients, as compared with
that of CEA and CYFRA21-1. In the present study, NSE
levels were associated with occurrence of metastases to
brain (P < 0.05), bone (P < 0.05), lymph nodes (P < 0.05),
mediastinum (P < 0.05) and peritoneal cavity (P < 0.05)
(Table 3). However, CEA levels correlated only with lymph
node metastasis (Additional file 3: Table S3A), while
CYFRA21-1 was associated with metastasis to brain
(Negative: 5.6%; moderate: 2.4%; high: 16.0%, P < 0.05),
and lymph node (Negative: 41.7%; moderate: 60%; high:
74.5%; P < 0.05) (Additional file 3: Table S3B).
In the present study, 18.3% of all subjects were small
cell lung cancer (SCLC) patients. In these patients, we
observed a correlation between increased levels of CEA
and occurrence of mediastinal and peritoneal metastasis (P
< 0.05) (Additional file 4: Table S4A); between increased
levels of CYFRA21-1 and liver metastasis (P < 0.05)
(Additional file 4: Table S4B); and between increased NSE
levels and occurrence of lymph node metastasis (Negative:
42.1%; moderate: 60.1%; high: 77.8%;P < 0.05) (Additional
file 4: Table S4C).
Table 3 The association analysis between NSE and SCC
No. (%)
Neg Moderate High Total P Value
(1–2 fold) >2 fold
(n = 110) (n = 70) (n = 35) (n = 215)
Basic Characteristics
Age
< 45 years 3 (2.7) 2 (2.9) 0 (0.0) 5 0.622
45–60 years 40 (36.4) 23 (32.8) 9 (25.7) 72
> 60 years 67 (60.9) 45 (64.3) 26 (74.3) 138
Sex
Male 101 (91.8) 61 (87.1) 30 (85.7) 192 0.463
Female 9 (8.2) 9 (12.9) 5 (14.3) 23
Stages
I + II 26 (23.6) 6 (8.6) 1 (2.8) 33 <0.05*
III + IV 80 (72.7) 62 (88.6) 33 (94.4) 175
Unknown 4 (3.7) 2 (2.8) 1 (2.8) 7
Smoke status
No 22 (20.0) 16 (22.9) 9 (25.7) 47 0.753
Yes 88 (80.0) 54 (77.1) 26 (74.3) 168
Metastasis
Brain
No 107 (97.3) 62 (88.6) 27 (77.1) 196 <0.05*
Yes 3 (2.7) 8 (11.4) 8 (22.9) 19
Bone
No 100 (90.9) 55 (78.6) 27 (77.1) 182 <0.05*
Yes 10 (9.1) 15 (21.4) 8 (22.9) 33
Liver
No 102 (92.7) 61 (87.1) 27 (77.1) 190 0.062
Yes 8 (7.3) 9 (12.9) 8 (22.9) 25
Adrenal gland
No 106 (96.4) 64 (91.4) 32 (91.4) 202 0.316
Yes 4 (3.6) 6 (8.6) 3 (8.6) 13
Lymph node
No 51 (46.4) 19 (27.1) 9 (25.7) 79 <0.05*
Yes 59 (53.6) 51 (72.9) 26 (74.3) 136
Intrapulmonary
No 96 (87.3) 58 (82.9) 31 (88.6) 185 0.632
Yes 14 (12.7) 12 (17.1) 4 (11.4) 30
Pleural
No 98 (89.1) 59 (84.3) 31 (88.6) 188 0.622
Yes 12 (10.9) 11 (15.7) 4 (11.4) 27
Mediastinal
No 108 (98.2) 61 (87.1) 34 (97.1) 203 <0.05*
Yes 2 (1.8) 9 (12.9) 1 (2.9) 12
Peritoneum
No 109 (99.1) 61 (87.1) 31 (88.6) 201 <0.05*
Yes 1 (0.9) 9 (12.9) 4 (11.4) 14
*p < 0.05, **p < 0.001
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Table 4 The analysis of positive numbers of biomarkers in all lung cancer patients
No. (%)
Neg Single Double Triple Total P Value
(1–10 fold) >10 fold
(n = 37) (n = 101) (n = 172) (n = 122) (n = 432)
Basic Characteristics
Age
< 45 2 (5.4) 5 (5.0) 12 (7.0) 9 (7.4) 28 0.057
45-60 22 (59.5) 50 (49.5) 61 (35.5) 43 (35.2) 176
> 60 13 (35.1) 46 (45.5) 99 (57.6) 70 (57.4) 228
Sex
Male 27 (73.0) 71 (70.3) 114 (66.3) 84 (68.9) 296 0.827
Female 10 (27.0) 30 (29.7) 58 (33.7) 38 (31.1) 136
Histological classification
SCC 12 (32.4) 29 (28.7) 49 (28.5) 29 (23.8) 119 0.772
ADC 19 (51.4) 53 (52.5) 90 (52.3) 63 (51.6) 225
SCLC 3 (8.1) 12 (11.9) 24 (14) 24 (19.7) 63
Others 3 (8.1) 7 (6.9) 9 (5.2) 6 (4.9) 25
Stages
I 5 (13.5) 8 (7.9) 5 (2.9) 0 (0) 18 <0.05*
II 2 (5.4) 6 (5.9) 5 (2.9) 4 (3.3) 17
III 14 (37.8) 34 (33.7) 43 (25) 37 (30.3) 128
IV 14 (37.8) 47 (46.5) 109 (63.4) 73 (59.8) 243
#Un. 2 (5.4) 6 (5.9) 10 (5.8) 8 (6.6) 26
Smoke status
No 16 (43.2) 54 (53.5) 73 (42.4) 48 (39.3) 191 0.178
Yes 21 (56.8) 47 (46.5) 99 (57.6) 74 (60.7) 241
Metastasis
Brain
No 34 (91.9) 91 (90.1) 143 (83.1) 103 (84.4) 371 0.277
Yes 3 (8.1) 10 (9.9) 29 (16.9) 19 (15.6) 61
Bone
No 33 (89.2) 87 (86.1) 127 (73.8) 88 (72.1) 335 <0.05*
Yes 4 (10.8) 14 (13.9) 45 (26.2) 34 (27.9) 97
Liver
No 36 (97.3) 94 (93.1) 155 (90.1) 106 (86.9) 391 0.199
Yes 1 (2.7) 7 (6.9) 17 (9.9) 16 (13.1) 41
Adrenal gland
No 36 (97.3) 98 (97) 154 (89.5) 117 (95.9) 405 0.086
Yes 1 (1.7) 3 (3.0) 18 (10.5) 5 (4.1) 27
Lymph node
No 25 (67.6) 45 (44.6) 69 (40.1) 32 (26.2) 171 <0.001**
Yes 12 (32.4) 56 (55.4) 103 (59.9) 90 (73.8) 261
Intrapulmonary
No 33 (89.2) 89 (88.1) 149 (86.6) 108 (88.5) 379 0.950
Yes 4 (10.8) 12 (11.9) 23 (13.4) 14 (11.5) 53
Pleural
No 33 (89.2) 89 (88.1) 142 (82.6) 104 (85.2) 368 0.552
Yes 4 (10.8) 12 (11.9) 30 (17.4) 18 (14.8) 64
Mediastinal
No 37 (100) 98 (97) 169 (98.3) 114 (93.4) 418 0.080
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Table 4 The analysis of positive numbers of biomarkers in all lung cancer patients (Continued)
Yes 0 (0.0) 3 (3.0) 3 (1.7) 8 (6.6) 14
Peritoneum
No 37 (100) 98 (93.7) 162 (94.2) 112 (91.8) 409 0.153
Yes 0 (0.0) 3 (6.3) 10 (5.8) 10 (8.2) 23
Validation group
No. (%)
Neg Single Double Triple Total P Value
(n = 27) (n = 118) (n = 161) (n = 130) (n = 436)
Basic Characteristics
Age
2 (7.4) 8 (6.8) 10 (6.2) 11 (8.5) 31 0.733
10 (37.0) 46 (39.0) 48 (29.8) 45 (34.6) 149
15 (55.6) 64 (54.2) 103 (64.0) 74 (56.9) 256
Sex
18 (66.7) 75 (63.6) 116 (72.0) 98 (75.4) 307 0.204
9 (33.3) 43 (36.4) 45 (28.0) 32 (24.6) 129
Histological classification
7 (25.9) 31 (26.3) 37 (23) 21 (16.2) 96 0.386
15 (55.6) 57 (48.3) 84 (52.2) 64 (49.2) 220
1 (3.7) 5 (4.2) 11 (6.8) 7 (5.4) 24
5 (18.5) 12 (10.2) 7 (4.3) 24 (18.5) 47
Stages
5 (18.5) 9 (7.6) 5 (3.1) 3 (2.3) 22 <0.05*
5 (18.5) 16 (13.6) 10 (6.2) 7 (5.4) 38
6 (22.2) 26 (22.0) 36 (22.4) 21 (16.2) 89
11 (40.7) 58 (49.2) 103 (64.0) 90 (69.2) 262
0 (0.0) 9 (7.6) 7 (4.3) 9 (19.2) 25
Smoke status
15 (55.6) 62 (52.5) 65 (40.4) 49 (37.7) 191 <0.05*
12 (44.4) 56 (47.5) 96 (59.6) 81 (62.3) 245
Metastasis
Brain
27 (100.0) 107 (90.7) 134 (83.2) 110 (84.6) 378 <0.05*
0 (0.0) 11 (9.3) 27 (16.8) 20 (15.4) 58
Bone
27 (100.0) 103 (87.3) 123 (76.4) 87 (66.9) 340 <0.001**
0 (0.0) 15 (12.7) 38 (23.6) 43 (33.1) 96
Liver
No 26 (96.3) 111 (94.1) 140 (87.0) 106 (81.5) 383 <0.05*
Yes 1 (3.7) 7 (5.9) 21 (13.0) 24 (18.5) 53
Adrenal gland
27 (100.0) 111 (94.1) 149 (92.5) 122 (93.8) 409 0.525
0 (0.0) 7 (5.9) 12 (7.5) 8 (6.2) 27
Lymph node
19 (70.4) 58 (49.2) 50 (31.1) 40 (30.8) 167 <0.001***
8 (29.6) 60 (50.8) 111 (68.9) 90 (69.2) 269
Intrapulmonary
26 (96.3) 105 (89.0) 130 (80.7) 114 (87.7) 375 0.064
1 (3.7) 13 (11.0) 31 (19.3) 16 (12.3) 61
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Table 4 The analysis of positive numbers of biomarkers in all lung cancer patients (Continued)
Pleural
25 (92.6) 107 (90.7) 129 (80.1) 104 (80.0) 365 <0.05*
2 (7.4) 11 (9.3) 32 (20.8) 26 (20.0) 71
Mediastinal
27 (100.0) 116 (98.3) 152 (94.4) 123 (94.6) 418 0.229
0 (0.0) 2 (1.7) 9 (5.6) 7 (5.4) 18
Peritoneum
27 (100.0) 110 (93.2) 144 (89.4) 118 (90.8) 399 0.269
0 (0.0) 8 (6.8) 17 (10.4) 12 (9.2) 37
Fig. 1 The survival status of lung cancer patients in training and validation groups a: CEA, b: CYFRA21-1, c: NSE, d: positive numbers *P< 0.05, **P< 0.001
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Increased positive numbers of biomarkers as predictors
of metastases
The analysis of increased positive numbers of bio-
markers in all lung cancer patients was performed in
training group and validation groups. In training group,
the numbers of negative, single, double and triple groups
were 37, 101, 172 and 122 cases, respectively, while 27,
118, 161 and 130 in the validation group. The number
TA and VA groups indicated less data deviation among
different groups. The results suggested strong correl-
ation of increased positive numbers with stages (TA: P <
0.05, VA: P < 0.05). In metastasis analysis, increased posi-
tive numbers related closely to occurrence of metastasis
in bone (TA: Neg 10.8%, Single 13.9%, Double 26.2%,
Triple 27.9%, P < 0.05; VA: Neg 0%, Single 12.7%, Double
23.6%, Triple 33.1%, P < 0.001) and lymph node (TA:
Neg 32.4%, Single 55.4%, Double 59.9%, Triple 73.8%, P
< 0.001; VA: Neg 29.6%, Single 50.8%, Double 68.9%,
Triple 69.2%, P < 0.001) (Table 4).
The application of 3-tier classification to all types of
lung cancers revealed that lymph node metastasis was
significantly associated with increased levels of bio-
markers (ADC P < 0.05; SCC P < 0.001; SCLC P < 0.05)
(Additional file 5: Table S5A-C). In ADC and SCC, in-
creased levels correlated with metastasis to both lymph
nodes and other organs (Additional file 5: Table S5A-C).
CYFRA21-1 levels correlated with survival in ADC, SCC
and SCLC
Kaplan-Meier survival curves were used to analyze mor-
tality at 3–5 years using SPSS19.0. The results of 3–5
year survival analyses indicated that presence of high
concentrations of CEA (TA P < 0.01; VA P < 0.01),
CYFRA21-1 (TA P < 0.001; VA P < 0.001), NSE (TA P <
0.05; VA P < 0.05) and positive numbers of biomarkers
(TA P < 0.001; VA P < 0.01) were closely associated with
survival status in both training group and validation
groups (Fig. 1a-d).
For ADC patients, high levels of CEA (P < 0.001),
CYFRA21-1 (P < 0.001), NSE (P < 0.05), and numbers of in-
creased biomarkers (P < 0.001), were all closely associated
with survival status of patients (Fig. 2). In SCC patients only
CYFRA21-1 was associated with mortality (Additional file 6:
Figure S1A). In SCLC patients, the high concentrations of
CYFRA21-1 (P < .05) and NSE (P < .05) were closely associ-
ated with survival status (Additional file 7: Figure S1B).
Multivariate Cox regression analysis to identify poor
prognostic factors
We observed a significant correlation between overall sur-
vival and CYFRA21-1, NSE and occurrence of metastasis.
Compared with negative group, the hazards ratio increased
1.226 in CYFRA21-1 moderate positive group (Confidence
Interval [CI]: 0.977–1.537) and 1.647 in CYFRA21-1 high
positive group (CI: 1.273–2.130, P < .001) (Table 5). For
NSE, we did not find a significant difference between
hazard risk and NSE moderate positive group (HR: 1.010,
CI: 0.808–1.263) but the HR increased 1.291 in NSE high
positive group compared with that of negative group (CI:
1.032–1.715, P < .05). As expected, occurrence of metastasis
was an independent predictor of poor prognosis (HR:
1.291, CI: 1.025–1.625, P < .05) (Table 5).
The specific histological grade analysis indicated that
high and moderate levels of serum CYFRA21-1 signifi-
cantly correlated with poor prognosis (HR: 1.860, CI:
Fig. 2 The survival functions in ADC patients correlated with different biomarkers *P < 0.05, **P < 0.001
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1.036–3.338, P < 0.05) in both ADC and SCLC patients
(HR: 1.365, CI: 0.514–3.624, P < 0.05) respectively (Table 6).
In SCC and SCLC patients, only occurrence of metastasis
was an independent factor for poor prognosis (Table 6).
When compared with negative groups, the number of posi-
tive biomarkers meant increased mortality risk in SCLC
(Single: HR 2.107, CI 0.460–9.644; double: HR 2.247 CI
0.386–13.077; triple: HR 2.508, CI 0.231–27.287) (Table 6)
although the associated P value was >0.05.
Lung cancer patients were then divided into three
groups according to stages (I + II, III and IV) and Cox
regression was conducted to analyze which biomarker
could act as independent factor of poor prognosis in
specific stage. The results indicated that CYFRA21-1
correlated dramatically with poor prognosis in all stages
of lung cancer patients (Stages I-II: HR 3.666 CI: 1.095–
12.279, P < 0.05; Stage III: HR 1.919 CI: 1.200–3.071, P <
0.05; Stage IV: HR 1.473 CI: 1.056–2.053, P < 0.05)
(Table 7 A-C), which confirm the importance of
CYFRA21-1 in poor prognosis in different stages of lung
cancer besides in specific histological classifications.
Discussion
Although several tumor markers for lung cancer have
been identified, none of them is specific for lung cancer
diagnosis. CYFRA21-1 has been reported as a poor
prognostic factor in various cancers, while NSE has been
associated with metastasis, and also used for monitoring
response to treatment in multiple myeloma. However,
these important biomarkers have not been thoroughly
investigated in lung cancer patients. In our study, ana-
lyses were performed to confirm the correlations
between serums CEA, CYFRA 21–1, NSE, as well as the
number of positive biomarkers and metastasis and
survival status of lung cancer patients.
All patients were randomly divided into training and
validation groups to confirm the grouping rationality of
this study. In brief, survival curves and associations with
clinical characteristics in the validation group were gen-
erally similar to those in training group, though there
were some non-significant inconsistence in sex and sev-
eral organs of metastasis. The results indicated that the
increased levels of CYFRA21-1 were strongly associated
with metastatic sites and histological grades of lung can-
cers in both training and validation groups. In specific
histological subtypes (ADC, SCC and SCLC) analyses,
we also found that CYFRA21-1 correlated more closely
to metastasis and survival status than CEA and NSE. To
our knowledge, these results have not been reported in
any of the earlier literatures.
In multivariate Cox regression analysis, only CYFRA21-1
and NSE were found to be independent predictors of prog-
nosis in lung cancer patients. When sub-grouped, only
CYFRA21-1was an independent predictor of poor progno-
sis in ADC (1.86-fold increased risk in high concentration
group) and SCLC (1.365-fold increased risk in moderate
group) but not CEA and NSE. Finally it was found that
Table 5 The multivariate analysis of lung cancer patients
Multivariate HR (95% CI) P value
Age
< 45 1[Reference] <0.001*
45–65 0.714 (0.513–0.994)
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CYFRA21-1 could act as independent factor in early
(I + II) and advanced stages (III and IV) of lung
cancer. Thus, CYFRA21-1 appears to be more im-
portant as a prognostic predictor than the other two
biomarkers.
Several reports have reported the useful roles of CEA
in diagnosis of ADC, CYFRA21-1 in SCC and NSE in
SCLC [18–21]. The increased levels of biomarkers are
known to correlate with cancer progression, with their
sensitivity depending largely on tumor stage and
histological classification [22]. In contrast with the previ-
ous reports [25], we found no correlation between in-
creased CEA levels and brain metastasis; however, we
did observe a correlation with bone, liver, pleural and
peritoneal metastases. The inconsistency could be ex-
plained by the smaller sample size (approximate N =
300). Research also indicated that high circulating con-
centrations of CYFRA21-1 and CEA were associated
with advanced stages of lung cancer; levels that were
two times higher than cutoff value were associated with
Table 6 The multivariate analysis of different histological classifications
Adenocarcinoma Squamous SCLC
(n = 445) (n = 215) (n = 159)
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value
Age
< 45 1[Reference] <0.05* 1[Reference] <0.05* 1[Reference] 0.104
45–65 0.733 (0.489–1.099) 0.866 (0.259–2.895) 0.769 (0.315–1.876)
> 65 1.084 (0.741–1.587) 1.712 (0.523–5.607) 1.237 (0.510–3.003)
Sex
Male 1[Reference] 0.338 1[Reference] 0.326 1[Reference] 0.354
Female 0.986 (0.715–1.122) 1.312 (0.763–2.254) 0.758 (0.421–1.363)
Stages
I + II 1[Reference] 0.415 1[Reference] 0.475 1[Reference] 0.902
III + IV 1.703 (1.035–2.802) 0.832 (0.495–1.399) 1.091 (0.465–2.556)
Smoke status
No 1[Reference] 0.177 1[Reference] 0.878 1[Reference] 0.076
Yes 0.807 (0.592–1.102) 1.037 (0.651–1.651) 0.518 (0.251–1.071)
CEA levels
Neg 1[Reference] 0.773 1[Reference] 0.295 1[Reference] 0.940
Moderate 1.085 (0.679–1.736) 1.244 (0.620–2.497) 0.850 (0.317–2.280)
High 1.169 (0.713–1.916) 0.700 (0.260–1.885) 0.894 (0.271–2.942)
CYFRA levels
Neg 1[Reference] <0.05* 1[Reference] 0.195 1[Reference] <0.05*
Moderate 1.161 (0.678–1.989) 1.057 (0.511–2.185) 1.365 (0.514–3.624)
High 1.860 (1.036–3.338) 1.502 (0.673–3.353) 0.907 (0.285–2.880)
NSE levels
Neg 1[Reference] 0.400 1[Reference] 0.329 1[Reference] 0.642
Moderate 1.025 (0.727–1.446) 1.025 (0.727–1.446) 0.952 (0.390–2.323)
High 1.154 (0.777–1.714) 1.154 (0.777–1.714) 1.342 (0.590–3.052)
Metastasis
No 1[Reference] 0.477 1[Reference] <0.05* 1[Reference] <0.05*
Yes 1.131 (0.806–1.585) 1.682 (1.052–2.688) 2.172 (1.180–3.998)
Positive numbers
Neg 1[Reference] 0.852 1[Reference] 0.334 1[Reference] 0.814
Single 1.334 (0.672–2.649) 0.748 (0.300–1.863) 2.107 (0.460–9.644)
Double 1.491 (0.557–3.992) 1.115 (0.327–3.803) 2.247 (0.386–13.077)
Triple 1.652 (0.517–5.276) 0.901 (0.183–4.449) 2.508 (0.231–27.287)
Zhang et al. BMC Cancer  (2017) 17:96 Page 11 of 14
Table 7 Cox regression analysis of CEA, CYFRA21-1 and NSE in
different stages of lung cancer
Multivariate HR (95% CI) P value
A I + II
Age
< 45 1[Reference] 0.405
45–65 0.390 (0.043–3.577)





























< 45 1[Reference] 0.147
45–65 0.492 (0.189–1.283)
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stage III and IV lung cancer patients [23]. Although
CYFRA21-1 appears to be the most sensitive and spe-
cific marker for NSCLC [26], its relationship with differ-
ent histological lung cancers has largely remained
unknown. An earlier report suggested that CYFRA was
a more sensitive and specific marker for SCC diagnosis
and was found to be of prognostic values in patients
with recurrent NSCLC receiving gefitinib therapy [27,
28]. In our study, however, high levels of CYFRA21-1
correlated with survival status in ADC and SCLC but
not in SCC patients. It also could be used as an inde-
pendent predictor of poor prognosis in ADC and SCLC
patients. Currently, NSE is the most widely used marker
for diagnosis and prognosis of SCLC patients [24]. In
our study, although positive levels of NSE significantly
correlated with survival in SCLC, it did not qualify as an
independent predictor for poor prognosis.
Conclusions
We designed this study to evaluate whether positive levels
of biomarkers correlate with occurrence of metastasis and
poor survival. The retrospective design and cross-sectional
nature of our study are limitations that did not permit
correlation analysis for all clinic pathological parameters.
Our study suggested the important role of CYFRA21-1 in
predicting occurrence of metastasis as well as poor progno-
sis in lung cancer patients. Our results could provide
important perspectives for diagnosis, prognosis and man-
agement of lung cancer.
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